EX-23.1 3 ea167011ex23-1_inmedpharma.htm CONSENT OF KPMG LLP

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

InMed Pharmaceuticals Inc.

 

We consent to the use of our report dated September 23, 2022, on the consolidated financial statements of InMed Pharmaceuticals Inc. incorporated by reference herein and to the reference to our firm under the heading “Experts” in the prospectus.

 

/s/ KPMG LLP

Chartered Professional Accountants

Vancouver, Canada

October 11, 2022